NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

Currently, about 35-40% of those that receive DCVax upfront will reach 3 year survival. There will still be space for later line therapy when the SOC fails.

The thing you have to ask yourself about the wait and alternatives, what would have happened if?

To be the standard of care means that you will receive a super majority share of the advanced markets. As a later line, you get a smaller share of what remains as rGBM.

Hmmm… I wonder why those other companies, you know, the ones with the approved trial designs with Hybrid ECAs as comparators, I wonder why they started with the much smaller market potential.